Characterize and monitor the therapeutic anti-fibrotic effect of CLDN-1 inhibition in liver spheroids (Innolink: 101.972 IP-LS)

• Unité de recherche: INNOSUISSE
• Numéro de projet: 62871.1 IP-LS
• Titre du projet anglais: Characterize and monitor the therapeutic anti-fibrotic effect of CLDN-1 inhibition in liver spheroids (Innolink: 101.972 IP-LS)

Description succincte (Allemand)

Characterize and monitor the therapeutic anti-fibrotic effect of CLDN-1 inhibition in liver spheroids (Innolink: 101.972 IP-LS)

Description succincte (Anglais)

Characterize and monitor the therapeutic anti-fibrotic effect of CLDN-1 inhibition in liver spheroids

Résumé des résultats (Abstract) (Allemand)

Alentis Therapeutics AG is implementing unique anti-claudin 1 monoclonal antibodies as a novel approach for the treatment of liver fibrosis. This project aims at leveraging 3D-in vitro models to identify translational makers of target engagement.